A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients

Cancer Investigation
William K OhMatthew R Smith

Abstract

Treatment options for patients with metastatic renal cell carcinoma are limited. Interferon-alpha has an overall response rate of 10-15% in phase II and III clinical trials and is considered a standard option for patients. Though the anti-estrogen toremifene has shown only modest single agent activity in renal cell carcinoma, evidence for synergy of anti-estrogens with interferon-alpha exists in renal cell and other cancers. Therefore, a phase II trial was undertaken to test the combination of interferon-alpha and toremifene in advanced renal cell carcinoma. Thirteen patients with measurable metastatic or unresectable local disease were treated with interferon-alpha at a dose of 5 million units/m2 three times a week and daily oral toremifene at 300 mg daily in divided doses. Patients were treated for 12 weeks and then restaged. Clinical response was the primary endpoint of the trial. Four patients (31%) had evidence of stable disease at 12 weeks, while the remaining nine patients (69%) progressed on treatment. Toxicity was moderate, with grade 2 or 3 fatigue, nausea and anorexia each noted in 31% of patients. We conclude that the combination of interferon-alpha plus toremifene demonstrates no significant activity in advanced re...Continue Reading

References

Feb 1, 1992·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M StahlH Poliwoda
Sep 21, 1991·JAMA : the Journal of the American Medical Association·S BaronT K Hughes
Nov 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J T HammI Shemano
Jun 22, 1990·Journal of Steroid Biochemistry·L KangasH Schellekens
Jan 1, 1989·Journal of Cancer Research and Clinical Oncology·F PorzsoltH Schönenberger
Jun 1, 1982·Urology·V J LanteriJ E Pontes
Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F HayesI Shemano
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A SchomburgJ Atzpodien
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R J Papac, M F Keohane
Jan 1, 1996·Breast Cancer Research and Treatment·L RepettoR Rosso
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·M M GershanovichM Anttila
Dec 24, 1997·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·D J Lindner, E C Borden
Apr 2, 1998·Journal of Neuro-oncology·S M ChangM D Prados

❮ Previous
Next ❯

Citations

Apr 1, 2003·Expert Opinion on Investigational Drugs·Mayer Fishman, Scott Antonia
Jun 12, 2004·Current Opinion in Clinical Nutrition and Metabolic Care·Eduardo J B RamosMichael M Meguid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.